Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo We investigated the antiviral activity of Arbidol, an antiviral chemical compound, against Coxsackie virus B5 (CVB 5 ) in vitro and in vivo. Arbidol not only prevented the cytopathic effect (CPE) of CVB 5 , as demonstrated in an MTT colorimetric assay, when added during or after viral infection, with a 50% inhibitory concentration (IC 50 ) from 2.66 to 6.62 μg/ml, but it also decreased the CVB 5 -RNA level in infected host cells, as shown in semi-quantitative RT-PCR. BALB/c mice were used as an animal model to test the Arbidol activity in vivo. Orally administered Arbidol at 50 mg/kg body weight/day (once a day) significantly reduced mean virus yields in the lungs and heart as well as mortality after infection for 6 days. Our results demonstrate that in vitro and in vivo infection with CVB 5 can be effectively treated by Arbidol. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Virology Springer Journals

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo

Loading next page...
1
 
/lp/springer_journal/antiviral-activity-of-arbidol-against-coxsackie-virus-b5-in-vitro-and-0dMZyrQ2K0

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Biomedicine; Infectious Diseases; Medical Microbiology ; Virology
ISSN
0304-8608
eISSN
1432-8798
DOI
10.1007/s00705-009-0346-4
pmid
19291363
Publisher site
See Article on Publisher Site

Abstract

We investigated the antiviral activity of Arbidol, an antiviral chemical compound, against Coxsackie virus B5 (CVB 5 ) in vitro and in vivo. Arbidol not only prevented the cytopathic effect (CPE) of CVB 5 , as demonstrated in an MTT colorimetric assay, when added during or after viral infection, with a 50% inhibitory concentration (IC 50 ) from 2.66 to 6.62 μg/ml, but it also decreased the CVB 5 -RNA level in infected host cells, as shown in semi-quantitative RT-PCR. BALB/c mice were used as an animal model to test the Arbidol activity in vivo. Orally administered Arbidol at 50 mg/kg body weight/day (once a day) significantly reduced mean virus yields in the lungs and heart as well as mortality after infection for 6 days. Our results demonstrate that in vitro and in vivo infection with CVB 5 can be effectively treated by Arbidol.

Journal

Archives of VirologySpringer Journals

Published: Apr 1, 2009

There are no references for this article.